A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors

Inclusion Criteria

• •Written informed consent
• •Age \>/= 18 years
• •Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
• •Patients for whom no standard curable therapy exists
• •Life expectancy of \>/= 12 weeks
• •Last dose of systemic anti-neoplastic therapy \> 21 days prior to first RO6927005 infusion
• •Palliative radiotherapy is allowed up to 2 weeks before the first RO6927005 infusion; palliative 8 Gy radiotherapy is allowed during therapy.
• •All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to Grade \</= 1, except alopecia (any grade) and Grade 2 peripheral neuropathy
• •Adequate hematological, liver, and renal function
• •Negative serum or urine pregnancy test within 7 days prior to study treatment in premenopausal women and women \</= 2 years after menopause (menopause is defined as amenorrhea for \>/= 2 years)
• •Agreement to use adequate contraceptive methods per protocol
• •Measurable and/or evaluable disease as per the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1) \[Groups 1, 2 of Part A and Group 3 of Part B\]
• •Metastatic and/or locally advanced malignant solid tumors enriched in tumor types known to be mesothelin expressing
• •Archival sample or fresh biopsy or tumor effusion must be available for retrospective mesothelin analysis
• •Histologically confirmed metastatic and/or advanced malignant mesothelin-positive solid tumors as determined by central pathology lab review
• •Patients must be willing to provide a screening and post-dose biopsy for biomarker analysis (extension phase only)
• •Mesothelin-positive refractory/recurrent solid tumors, other than malignant pleural mesothelioma (MPM) and pancreatic ductal adenocarcinoma (PDA) (Group 1 only)
• •Mesothelin-positive refractory/recurrent MPM (Group 2 only)
• •Histologically confirmed metastatic and/or advanced mesothelin-positive PDA as determined by central pathology lab review
• •In the extension phase, patients must be willing to provide a screening and post-dose biopsy for biomarker analysis